Virus sequences posted to a pre-print sequence site Maindicate the infections are a resurgence of the West African outbreak of 2013–2016. The continuous threat of Ebola Virus Disease is manifest in a new outbreak in Guinea, beginning Janu. Another outbreak in the Democratic Republic of the Congo, this time in the Equateur Province, shown by sequencing to be a unique variant, was brought under control by November 2020. As of July 2020, 303,000 people had been vaccinated. Part of the success in controlling the epidemic was the availability of a vaccine based on recombinant, replication competent, vesicular stomatitis virus expressing a surface glycoprotein of Ebola virus now licensed by the US FDA called rVSV-ZEBOV-GP, first utilized in ring vaccination trials during the previous epidemic. Beginning in August 2018 in the North Kivu region of the Democratic Republic of the Congo, the outbreak was also extended in duration compared to pre-2013 outbreaks and was declared over on 25 June 2020 with 3,470 total cases and 2,287 deaths. An epidemic in Central Africa presented additional serious concerns, because, like the 2013–2016 epidemic, it was affecting urban areas, as well as areas of active conflict. In West Africa, in late 2013 and early 2014, the level of concern for Ebola virus disease (EVD) increased because it spread quickly, reached densely-populated areas, and persisted for the longest duration, resulting in 28,639 infections and 11,316 deaths. EBOV has been responsible for the largest outbreaks, with the most widespread epidemics occurring recently in Central Africa. There are four Ebolaviruses which cause the most severe disease in humans: Ebola virus (EBOV), Bundibugyo virus (BDBV), Sudan virus (SUDV) and Taï Forest virus (TAFV). The average case fatality rate is around 50% and has been reported to be as high as 90%. Filoviruses are emerging pathogens that cause acute fever with high fatality rate and present a public health threat that impacts far outside the immediate area of an outbreak.
0 kommentar(er)
